XXXX for @entity1596 associated with @entity4932 : value and requirement for additional anti-inflammatory medication.

@entity1 @entity500 @entity1596 @entity532 @entity726 @entity4932 @entity5502 @entity205 @entity2790 @entity1500 @entity230 @entity1499
PURPOSE: To study the value of @entity1499 ( @entity1500 ) and the requirement for additional anti-inflammatory drugs for the treatment of severe @entity5502 associated with @entity4932 ( @entity4932 ). METHODS: Institutional study of 35 consecutive @entity1 with @entity4932 started on @entity1500 as the single systemic immunosuppressive drug for the treatment of associated @entity5502 . The clinical epidemiologic data, course of visual acuity (VA), development of complications, and the need for additional anti-inflammatory drugs were analyzed. RESULTS: Mean follow-up with @entity1500 treatment was 27.6 months. @entity532 were present in 31 @entity1 before @entity1500 treatment. With @entity1500 , quiescence of @entity1596 was obtained with (n=21) or without (n=4) additional topical steroids. Additional systemic immunosuppressive drugs were required in another 7 @entity1 : @entity205 (n=4), @entity500 (n=1), infliximab (n=1), or etanercept (n=1). Three @entity1 had active @entity1596 at the end of the follow-up period. During @entity1500 therapy, @entity1596 first developed in the unaffected fellow eyes in 2 @entity1 , and secondary @entity726 or @entity2790 occurred in 7 @entity1 . The VA deteriorated in 6, improved in 13, and was stable in the remaining eyes. CONCLUSIONS: The data suggest that @entity1500 is very effective in controlling inflammation of @entity1596 in @entity1 with @entity4932 . However, additional topical @entity230 or systemic immunosuppressive drugs are often required.
